Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease

2021 ◽  
Author(s):  
Keeley M. Fairbrass ◽  
Christian P. Selinger ◽  
David J. Gracie ◽  
Alexander C. Ford
Keyword(s):  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Bowel Disease ◽  
Rome Iii ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
Rome Iv

scholarly journals P580 Irritable bowel syndrome in inflammatory bowel disease after remission: correlation with remission patterns and inflammation

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S487-S488
Author(s):  
O Sezgin ◽  
B Boztepe ◽  
E Altintas ◽  
D Çelikcan
Keyword(s):  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Bowel Disease ◽  
Clinical Remission ◽  
Inflammation Markers ◽  
Biopsy Specimens ◽  
Endoscopic Remission ◽  
Rome Iii ◽  
Inflammatory Bowel ◽  
Irritable Bowel

Abstract Background The objective of the study is to establish the frequency of irritable bowel syndrome (IBS) in patients with inflammatory bowel disease in clinical and deep remission and correlation with inflammation markers. Methods In this study, patients with ulcerative colitis (UC), and with Crohn disease (CD) in clinical remission for at least 6 months enrolled. All of the patients underwent colonoscopy and biopsy specimens were taken to evaluate endoscopic and histopathologic remission. All of the cases were given a questionnaire using the Rome III criteria for IBS and faecal specimens for calprotectin analysis, and blood samples for CRP, sedimentation rate and fibrinogen levels were taken. Results IBS frequency was 20.9% in UC cases in clinical remission, 28.9% in CD cases, and did not vary by the presence or absence of endoscopic remission (20,5% vs.22,2% in UC, p:0,727, 25% vs.33,3% in CD, p:0,837) or histopathologic remission (15,7% vs.26,6% in UC, p:0,723, 21,4% vs.33,3% in CD respectively, p:0,999). The incidence of IBS did not change statistically with deepening of remission in both diseases. It was not related to inflammation markers Conclusion IBS frequency among IBD patients in clinical remission was 21–29% and did not vary by the presence or absence of endoscopic or histopathologic remission or by inflammation markers levels. This suggests that IBS may not be related to ongoing subclinical inflammation in IBD in remission.

Sign in / Sign up

Export Citation Format

Share Document